Adoptive Cellular Therapy Targeting Recurrent Pediatric Brain Cancers During Hematopoietic Recovery from High-Dose Chemotherapy
Abstract
A phase I/II clinical trial evaluating the feasibility, safety, and clinical efficacy of adoptive cellular therapy combined with dendritic cell (DC) vaccination targeting recurrent medulloblastoma and PNETs was opened for enrollment at Duke University Medical Center during the previous funding period (Year 1). DC generation and T cell expansion from archived post-induction chemotherapy specimens from five patients with medulloblastoma was attempted and mature RNA-pulsed DCs were successfully generated from 3 of 5 specimens and successful T cell expansion was achieved from these samples. Limitations in the yield of DCs and T cells from these specimens prompted a modification to the protocol to collect a leukapheresis sample prior to induction chemotherapy. A web-based clinical database for patient and laboratory data storage (Oracle Clinical) has been created by the Duke Comprehensive Cancer Center Bioinformatics team and is undergoing final beta testing and personnel training for release. Advertising efforts have increased awareness and recent referrals to the study protocol. Two subjects have been enrolled on the protocol, one removed due to final pathology other than medulloblastoma/PNET, and the other scheduled for surgical resection next week. Two additional subjects are currently undergoing screening for enrollment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2011
- Accession Number
- ADA551893
Entities
People
- Duane A Mitchell
Organizations
- Duke University